Systemic Anti-Cancer Therapy Regimen Library
AALL1131 [very high risk] - Interim maintenance 1 (LEU ALL precursor B-cell - AALL1131 [very high risk])
Treatment Overview
Starts on day 57 of Consolidation or count recovery, whichever occurs later.
Prior to each dose of high dose metHOTREXATe neutrophils should be greater than 0.75 x 109/L and platelets greater than 75 x 109/L.
High dose metHOTREXATe
- metHOTREXATe levels MUST be measured once every 24 hours.
- Intravenous alkalinized fluids MUST be commenced at least 6 hours before the start of metHOTREXATe infusion and MUST continue until the metHOTREXATe serum level is less than 0.05 µmol/L – 0.1 µmol/L (level as per institutional practice). Additional oral alkalinization can be considered as Ural® 2 sachets orally the night before and 2 sachets the morning of high dose metHOTREXATe infusion.
- Before commencing the high dose metHOTREXATe infusion, urinary pH MUST be 7.5 or above (pH 7.5 to 8.0).
- Closely monitor renal function, electrolytes, fluid balance, and weight.
- foliNIc acid MUST start 42 hours after start of metHOTREXATe infusion and MUST continue to be administered for a minimum of 3 doses AND until serum metHOTREXATe level is less than 0.05 µmol/L – 0.1 µmol/L (level as per institutional practice).
Cycle 1 - 63 days
Intrathecal metHOTREXATe:
- Administer within 6 hours either side of high dose metHOTREXATe infusion.
- For Ommaya reservoir reduce dose to 6 mg intraventricularly.
foliNIc acid: MUST start 42 hours after start of metHOTREXATe infusion and MUST continue to be administered every 6 hours for at least 3 doses AND until serum metHOTREXATe level is less than 0.05 µmol/L – 0.1 µmol/L (level as per institutional practice).
mercaptOPURine: Consider thiopurine methyltransferase (TPMT) testing and NUDT15 screening for specific patients.
Cycle details
Cycle 1 - 63 days
Medication | Dose | Route | Days | Max Duration |
---|---|---|---|---|
metHOTREXATe * | 15 mg | intrathecal injection | 1, 29 | |
vinCRISTine * | 1.5 mg/m² Cap dose per administration at: 2 mg | intravenous | 1, 15, 29, 43 |
10 minutes |
potassium chloride 20mmol/1000mL + sodium chloride 0.18% + glucose 4% | 125 mL/m²/hour | intravenous | 1 to 4, 15 to 18, 29 to 32, 43 to 46 |
|
sodium bicarbonate | 50 mmol | intravenous | 1 to 4, 15 to 18, 29 to 32, 43 to 46 |
|
acetazolamide * | 250 mg Four times daily | oral administration | 1 to 4, 15 to 18, 29 to 32, 43 to 46 |
|
metHOTREXATe | 500 mg/m² | intravenous | 1, 15, 29, 43 |
30 minutes |
metHOTREXATe | 4500 mg/m² | intravenous | 1, 15, 29, 43 |
23.5 hours |
foliNIc acid (as calcium folinate) | 15 mg/m² Every six hours | intravenous | 2, 3, 4, 16, 17, 18, 30, 31, 32, 44, 45, 46 |
2 minutes |
mercaptOPURine * | 25 mg/m² Once daily | oral administration | 1 to 56 |
Intrathecal metHOTREXATe:
- Administer within 6 hours either side of high dose metHOTREXATe infusion.
- For Ommaya reservoir reduce dose to 6 mg intraventricularly.
foliNIc acid: MUST start 42 hours after start of metHOTREXATe infusion and MUST continue to be administered every 6 hours for at least 3 doses AND until serum metHOTREXATe level is less than 0.05 µmol/L – 0.1 µmol/L (level as per institutional practice).
mercaptOPURine: Consider thiopurine methyltransferase (TPMT) testing and NUDT15 screening for specific patients.
Full details
Cycle 1 - 63 days
Day: 1
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
metHOTREXATe * | 15 mg | intrathecal injection |
Instructions:
|
|
vinCRISTine * | 1.5 mg/m² Cap dose per administration at: 2 mg | intravenous | 10 minutes |
Instructions:
|
potassium chloride 20mmol/1000mL + sodium chloride 0.18% + glucose 4% | 125 mL/m²/hour | intravenous |
Instructions:
|
|
sodium bicarbonate | 50 mmol | intravenous |
Instructions:
|
|
acetazolamide * | 250 mg Four times daily | oral administration |
Instructions:
When required.
|
|
metHOTREXATe | 500 mg/m² | intravenous | 30 minutes |
Instructions:
Neutrophils should be greater than 0.75 x 109/L and platelets greater than 75 x 109/L prior to commencing high dose metHOTREXATe. |
metHOTREXATe | 4500 mg/m² | intravenous | 23.5 hours |
Instructions:
Continuous infusion over 23.5 hours, starting immediately after the 30 minute metHOTREXATe infusion (Total metHOTREXATe infusion must be completed within 24 hours). |
mercaptOPURine * | 25 mg/m² Once daily | oral administration |
Instructions:
|
Day: 2
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
potassium chloride 20mmol/1000mL + sodium chloride 0.18% + glucose 4% | 125 mL/m²/hour | intravenous |
Instructions:
|
|
sodium bicarbonate | 50 mmol | intravenous |
Instructions:
|
|
acetazolamide * | 250 mg Four times daily | oral administration |
Instructions:
When required.
|
|
foliNIc acid (as calcium folinate) | 15 mg/m² Every six hours | intravenous | 2 minutes |
Instructions:
|
mercaptOPURine * | 25 mg/m² Once daily | oral administration |
Instructions:
|
Day: 3
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
potassium chloride 20mmol/1000mL + sodium chloride 0.18% + glucose 4% | 125 mL/m²/hour | intravenous |
Instructions:
|
|
sodium bicarbonate | 50 mmol | intravenous |
Instructions:
|
|
acetazolamide * | 250 mg Four times daily | oral administration |
Instructions:
When required.
|
|
foliNIc acid (as calcium folinate) | 15 mg/m² Every six hours | intravenous | 2 minutes |
Instructions:
|
mercaptOPURine * | 25 mg/m² Once daily | oral administration |
Instructions:
|
Day: 4
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
potassium chloride 20mmol/1000mL + sodium chloride 0.18% + glucose 4% | 125 mL/m²/hour | intravenous |
Instructions:
|
|
sodium bicarbonate | 50 mmol | intravenous |
Instructions:
|
|
acetazolamide * | 250 mg Four times daily | oral administration |
Instructions:
When required.
|
|
foliNIc acid (as calcium folinate) | 15 mg/m² Every six hours | intravenous | 2 minutes |
Instructions:
|
mercaptOPURine * | 25 mg/m² Once daily | oral administration |
Instructions:
|
Day: 5
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
mercaptOPURine * | 25 mg/m² Once daily | oral administration |
Instructions:
|
Day: 6
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
mercaptOPURine * | 25 mg/m² Once daily | oral administration |
Instructions:
|
Day: 7
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
mercaptOPURine * | 25 mg/m² Once daily | oral administration |
Instructions:
|
Day: 8
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
mercaptOPURine * | 25 mg/m² Once daily | oral administration |
Instructions:
|
Day: 9
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
mercaptOPURine * | 25 mg/m² Once daily | oral administration |
Instructions:
|
Day: 10
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
mercaptOPURine * | 25 mg/m² Once daily | oral administration |
Instructions:
|
Day: 11
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
mercaptOPURine * | 25 mg/m² Once daily | oral administration |
Instructions:
|
Day: 12
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
mercaptOPURine * | 25 mg/m² Once daily | oral administration |
Instructions:
|
Day: 13
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
mercaptOPURine * | 25 mg/m² Once daily | oral administration |
Instructions:
|
Day: 14
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
mercaptOPURine * | 25 mg/m² Once daily | oral administration |
Instructions:
|
Day: 15
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
vinCRISTine * | 1.5 mg/m² Cap dose per administration at: 2 mg | intravenous | 10 minutes |
Instructions:
|
potassium chloride 20mmol/1000mL + sodium chloride 0.18% + glucose 4% | 125 mL/m²/hour | intravenous |
Instructions:
|
|
sodium bicarbonate | 50 mmol | intravenous |
Instructions:
|
|
acetazolamide * | 250 mg Four times daily | oral administration |
Instructions:
When required.
|
|
metHOTREXATe | 500 mg/m² | intravenous | 30 minutes |
Instructions:
Neutrophils should be greater than 0.75 x 109/L and platelets greater than 75 x 109/L prior to commencing high dose metHOTREXATe. |
metHOTREXATe | 4500 mg/m² | intravenous | 23.5 hours |
Instructions:
Continuous infusion over 23.5 hours, starting immediately after the 30 minute metHOTREXATe infusion (Total metHOTREXATe infusion must be completed within 24 hours). |
mercaptOPURine * | 25 mg/m² Once daily | oral administration |
Instructions:
|
Day: 16
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
potassium chloride 20mmol/1000mL + sodium chloride 0.18% + glucose 4% | 125 mL/m²/hour | intravenous |
Instructions:
|
|
sodium bicarbonate | 50 mmol | intravenous |
Instructions:
|
|
acetazolamide * | 250 mg Four times daily | oral administration |
Instructions:
When required.
|
|
foliNIc acid (as calcium folinate) | 15 mg/m² Every six hours | intravenous | 2 minutes |
Instructions:
|
mercaptOPURine * | 25 mg/m² Once daily | oral administration |
Instructions:
|
Day: 17
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
potassium chloride 20mmol/1000mL + sodium chloride 0.18% + glucose 4% | 125 mL/m²/hour | intravenous |
Instructions:
|
|
sodium bicarbonate | 50 mmol | intravenous |
Instructions:
|
|
acetazolamide * | 250 mg Four times daily | oral administration |
Instructions:
When required.
|
|
foliNIc acid (as calcium folinate) | 15 mg/m² Every six hours | intravenous | 2 minutes |
Instructions:
|
mercaptOPURine * | 25 mg/m² Once daily | oral administration |
Instructions:
|
Day: 18
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
potassium chloride 20mmol/1000mL + sodium chloride 0.18% + glucose 4% | 125 mL/m²/hour | intravenous |
Instructions:
|
|
sodium bicarbonate | 50 mmol | intravenous |
Instructions:
|
|
acetazolamide * | 250 mg Four times daily | oral administration |
Instructions:
When required.
|
|
foliNIc acid (as calcium folinate) | 15 mg/m² Every six hours | intravenous | 2 minutes |
Instructions:
|
mercaptOPURine * | 25 mg/m² Once daily | oral administration |
Instructions:
|
Day: 19
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
mercaptOPURine * | 25 mg/m² Once daily | oral administration |
Instructions:
|
Day: 20
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
mercaptOPURine * | 25 mg/m² Once daily | oral administration |
Instructions:
|
Day: 21
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
mercaptOPURine * | 25 mg/m² Once daily | oral administration |
Instructions:
|
Day: 22
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
mercaptOPURine * | 25 mg/m² Once daily | oral administration |
Instructions:
|
Day: 23
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
mercaptOPURine * | 25 mg/m² Once daily | oral administration |
Instructions:
|
Day: 24
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
mercaptOPURine * | 25 mg/m² Once daily | oral administration |
Instructions:
|
Day: 25
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
mercaptOPURine * | 25 mg/m² Once daily | oral administration |
Instructions:
|
Day: 26
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
mercaptOPURine * | 25 mg/m² Once daily | oral administration |
Instructions:
|
Day: 27
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
mercaptOPURine * | 25 mg/m² Once daily | oral administration |
Instructions:
|
Day: 28
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
mercaptOPURine * | 25 mg/m² Once daily | oral administration |
Instructions:
|
Day: 29
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
metHOTREXATe * | 15 mg | intrathecal injection |
Instructions:
|
|
vinCRISTine * | 1.5 mg/m² Cap dose per administration at: 2 mg | intravenous | 10 minutes |
Instructions:
|
potassium chloride 20mmol/1000mL + sodium chloride 0.18% + glucose 4% | 125 mL/m²/hour | intravenous |
Instructions:
|
|
sodium bicarbonate | 50 mmol | intravenous |
Instructions:
|
|
acetazolamide * | 250 mg Four times daily | oral administration |
Instructions:
When required.
|
|
metHOTREXATe | 500 mg/m² | intravenous | 30 minutes |
Instructions:
Neutrophils should be greater than 0.75 x 109/L and platelets greater than 75 x 109/L prior to commencing high dose metHOTREXATe. |
metHOTREXATe | 4500 mg/m² | intravenous | 23.5 hours |
Instructions:
Continuous infusion over 23.5 hours, starting immediately after the 30 minute metHOTREXATe infusion (Total metHOTREXATe infusion must be completed within 24 hours). |
mercaptOPURine * | 25 mg/m² Once daily | oral administration |
Instructions:
|
Day: 30
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
potassium chloride 20mmol/1000mL + sodium chloride 0.18% + glucose 4% | 125 mL/m²/hour | intravenous |
Instructions:
|
|
sodium bicarbonate | 50 mmol | intravenous |
Instructions:
|
|
acetazolamide * | 250 mg Four times daily | oral administration |
Instructions:
When required.
|
|
foliNIc acid (as calcium folinate) | 15 mg/m² Every six hours | intravenous | 2 minutes |
Instructions:
|
mercaptOPURine * | 25 mg/m² Once daily | oral administration |
Instructions:
|
Day: 31
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
potassium chloride 20mmol/1000mL + sodium chloride 0.18% + glucose 4% | 125 mL/m²/hour | intravenous |
Instructions:
|
|
sodium bicarbonate | 50 mmol | intravenous |
Instructions:
|
|
acetazolamide * | 250 mg Four times daily | oral administration |
Instructions:
When required.
|
|
foliNIc acid (as calcium folinate) | 15 mg/m² Every six hours | intravenous | 2 minutes |
Instructions:
|
mercaptOPURine * | 25 mg/m² Once daily | oral administration |
Instructions:
|
Day: 32
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
potassium chloride 20mmol/1000mL + sodium chloride 0.18% + glucose 4% | 125 mL/m²/hour | intravenous |
Instructions:
|
|
sodium bicarbonate | 50 mmol | intravenous |
Instructions:
|
|
acetazolamide * | 250 mg Four times daily | oral administration |
Instructions:
When required.
|
|
foliNIc acid (as calcium folinate) | 15 mg/m² Every six hours | intravenous | 2 minutes |
Instructions:
|
mercaptOPURine * | 25 mg/m² Once daily | oral administration |
Instructions:
|
Day: 33
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
mercaptOPURine * | 25 mg/m² Once daily | oral administration |
Instructions:
|
Day: 34
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
mercaptOPURine * | 25 mg/m² Once daily | oral administration |
Instructions:
|
Day: 35
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
mercaptOPURine * | 25 mg/m² Once daily | oral administration |
Instructions:
|
Day: 36
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
mercaptOPURine * | 25 mg/m² Once daily | oral administration |
Instructions:
|
Day: 37
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
mercaptOPURine * | 25 mg/m² Once daily | oral administration |
Instructions:
|
Day: 38
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
mercaptOPURine * | 25 mg/m² Once daily | oral administration |
Instructions:
|
Day: 39
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
mercaptOPURine * | 25 mg/m² Once daily | oral administration |
Instructions:
|
Day: 40
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
mercaptOPURine * | 25 mg/m² Once daily | oral administration |
Instructions:
|
Day: 41
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
mercaptOPURine * | 25 mg/m² Once daily | oral administration |
Instructions:
|
Day: 42
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
mercaptOPURine * | 25 mg/m² Once daily | oral administration |
Instructions:
|
Day: 43
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
vinCRISTine * | 1.5 mg/m² Cap dose per administration at: 2 mg | intravenous | 10 minutes |
Instructions:
|
potassium chloride 20mmol/1000mL + sodium chloride 0.18% + glucose 4% | 125 mL/m²/hour | intravenous |
Instructions:
|
|
sodium bicarbonate | 50 mmol | intravenous |
Instructions:
|
|
acetazolamide * | 250 mg Four times daily | oral administration |
Instructions:
When required.
|
|
metHOTREXATe | 500 mg/m² | intravenous | 30 minutes |
Instructions:
Neutrophils should be greater than 0.75 x 109/L and platelets greater than 75 x 109/L prior to commencing high dose metHOTREXATe. |
metHOTREXATe | 4500 mg/m² | intravenous | 23.5 hours |
Instructions:
Continuous infusion over 23.5 hours, starting immediately after the 30 minute metHOTREXATe infusion (Total metHOTREXATe infusion must be completed within 24 hours). |
mercaptOPURine * | 25 mg/m² Once daily | oral administration |
Instructions:
|
Day: 44
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
potassium chloride 20mmol/1000mL + sodium chloride 0.18% + glucose 4% | 125 mL/m²/hour | intravenous |
Instructions:
|
|
sodium bicarbonate | 50 mmol | intravenous |
Instructions:
|
|
acetazolamide * | 250 mg Four times daily | oral administration |
Instructions:
When required.
|
|
foliNIc acid (as calcium folinate) | 15 mg/m² Every six hours | intravenous | 2 minutes |
Instructions:
|
mercaptOPURine * | 25 mg/m² Once daily | oral administration |
Instructions:
|
Day: 45
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
potassium chloride 20mmol/1000mL + sodium chloride 0.18% + glucose 4% | 125 mL/m²/hour | intravenous |
Instructions:
|
|
sodium bicarbonate | 50 mmol | intravenous |
Instructions:
|
|
acetazolamide * | 250 mg Four times daily | oral administration |
Instructions:
When required.
|
|
foliNIc acid (as calcium folinate) | 15 mg/m² Every six hours | intravenous | 2 minutes |
Instructions:
|
mercaptOPURine * | 25 mg/m² Once daily | oral administration |
Instructions:
|
Day: 46
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
potassium chloride 20mmol/1000mL + sodium chloride 0.18% + glucose 4% | 125 mL/m²/hour | intravenous |
Instructions:
|
|
sodium bicarbonate | 50 mmol | intravenous |
Instructions:
|
|
acetazolamide * | 250 mg Four times daily | oral administration |
Instructions:
When required.
|
|
foliNIc acid (as calcium folinate) | 15 mg/m² Every six hours | intravenous | 2 minutes |
Instructions:
|
mercaptOPURine * | 25 mg/m² Once daily | oral administration |
Instructions:
|
Day: 47
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
mercaptOPURine * | 25 mg/m² Once daily | oral administration |
Instructions:
|
Day: 48
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
mercaptOPURine * | 25 mg/m² Once daily | oral administration |
Instructions:
|
Day: 49
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
mercaptOPURine * | 25 mg/m² Once daily | oral administration |
Instructions:
|
Day: 50
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
mercaptOPURine * | 25 mg/m² Once daily | oral administration |
Instructions:
|
Day: 51
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
mercaptOPURine * | 25 mg/m² Once daily | oral administration |
Instructions:
|
Day: 52
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
mercaptOPURine * | 25 mg/m² Once daily | oral administration |
Instructions:
|
Day: 53
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
mercaptOPURine * | 25 mg/m² Once daily | oral administration |
Instructions:
|
Day: 54
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
mercaptOPURine * | 25 mg/m² Once daily | oral administration |
Instructions:
|
Day: 55
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
mercaptOPURine * | 25 mg/m² Once daily | oral administration |
Instructions:
|
Day: 56
Medication | Dose | Route | Max duration | Details |
---|---|---|---|---|
mercaptOPURine * | 25 mg/m² Once daily | oral administration |
Instructions:
|
Supportive Care Factors
Factor | Value |
---|---|
Antifungal prophylaxis: | Routine antifungal prophylaxis recommended |
Antiviral prophylaxis for herpes virus: | Routine antiviral prophylaxis recommended |
Constipation risk: | Consider prescribing laxatives with this treatment |
Emetogenicity: | Variable |
Folinic acid rescue for high dose methotrexate: | Mandatory |
Hydration: | Routine hydration recommended |
Pneumocystis jirovecii pneumonia (PJP) prophylaxis: | Routine antibiotic prophylaxis recommended |
Antifungal prophylaxis: Inhibition of CYP3A4 by azole antifungals may lead to reduced vinCRISTine clearance and increased toxicities. Strategies to avoid this interaction may include a washout period after azole administration or using a non-azole antifungal for prophylaxis.
Antiviral prophylaxis for hepatitis B virus: Guidance is limited to high-risk anti-cancer medicines. Clinicians will need to assess individual patient risk for other anti-cancer medicines.
Emetogenicity:
- MEDIUM days 1, 15, 29, 43, high dose metHOTREXATe may be highly emetogenic in certain patients.
- MINIMAL to LOW (mercaptOPURine).
PJP prophylaxis: If trimethoprim + sulfamethoxazole is used as prophylaxis, it is recommended to withhold at least 48 hours prior to high dose metHOTREXATe administration and until serum metHOTREXATe level is less than 0.05 µmol/L – 0.1µmol/L (as per institutional practice).
References
No references
* The medicines, doses, combinations, and schedule in this treatment regimen have been carefully reviewed against international best practice guidelines by specialists in medical oncology around New Zealand and this advice has been accepted for publication by Te Aho o Te Kahu (the Cancer Control Agency). Sometimes medicines that are used in routine clinical practice have not been through a formal review process by the NZ Medicines Regulator Medsafe and are therefore considered unapproved or off-label. These medicines are legally able to be prescribed through sections 25 and 29 of the Medicines Act and by obtaining informed consent from patients. All treatment regimens listed on this website have been through robust peer review and are considered an accepted standard of care, whether prescribed through sections 25 or 29 or carrying formal Medsafe Approval.
s29: This symbol indicates that some formulations of the associated medicine are legally only able to be prescribed under section 29 of the Medicines Act. You can see which formulations are section 29 by hovering over the s29 symbol. You can access full medication details from the New Zealand Formulary by clicking on the medication name. Each clinician retains full responsibility for ensuring they have complied with all relevant obligations and requirements of section 29 including obtaining informed patient consent prior to prescribing the applicable medicine.